Breaking chains of gluten-immunogenic peptides
Solutions for gluten-related disorders
AMYRA
Biotech AG
AMYRA Biotech AG
AMYRA Biotech AG is a private Swiss joint stock company, founded in 2013.
The multidisciplinary team brings together complementary expertise in drug development, biotechnology, immunology, medicine and business.
AMYRA collaborates intensively with universities, research institutes, industry partners and healthcare professionals.
AMYRA's mission is to deliver effective and safe treatments for gluten related disorders.
AMYRA's mission is to deliver effective and safe treatments for gluten related disorders.
A unique approach
AMYRA Products
Foundation
Scientific research has shown that partially digested gluten fragments, known as gluten immunogenic peptides (GIPs) trigger an autoimmune response in genetically predisposed people, namely celiac disease.
GIPs also play a role in the immune pathology of non-celiac gluten sensitivity, a clinical syndrome distinct from celiac disease.
AMYRA develops GIP-degrading enzymes as oral treatments for both celiac disease and non-celiac gluten sensitivity.
development
Latest Updates
December 2020
In recent years, public awareness of gluten- related disorders has become universal. Non- celiac gluten sensitivity (NCGS) and celiac disease (CeD) are two clinically distinct gluten- related disorders that constitute a major public health issue.
Q2 2020
AMY01 is currently undergoing a GRAS (generally recognized as safe) notice application in the US and will soon undergo the “novel food” application in Europe.
AMYRA intends to partner the dietary supplement AMY01 with a global consumer health company for marketing, sales and distribution. This will soon give people affected by non-celiac gluten sensitivity access to our product .
